RISK ASSESSMENT FOR AFLATOXIN - AN EVALUATION BASED ON THE MULTISTAGEMODEL

Lifetime cancer potency of alfatoxin was assessed based on the Yeh et al. study from China in which both aflatoxin exposure and hepatitis B prevalence were measured. This study provides the best available infor mation for estimating the carcinogenic risk posed by aflatoxin to the U.S. population. Cancer potency of aflatoxin was estimated using a bio logically motivated risk assessment model. The best estimate of aflato xin potency was 9 (mg/kg/day)-1 for individuals negative for hepatitis B and 230 (mg/kg/day)-1 for individuals positive for hepatitis B.